Targeting the sphingosine-1-phosphate axis in cancer, inflammation and beyond (original) (raw)

• Zhang, H. et al. Sphingosine-1-phosphate, a novel lipid, involved in cellular proliferation. J. Cell Biol. 114, 155–167 (1991). This paper provided the first evidence to demonstrate that S1P is a bioactive lipid produced from sphingosine that regulates cellular proliferation.
  Article CAS PubMed Google Scholar
• Fyrst, H. & Saba, J. D. An update on sphingosine-1-phosphate and other sphingolipid mediators. Nature Chem. Biol. 6, 489–497 (2010).
  Article CAS Google Scholar
• Pyne, S. & Pyne, N. J. Translational aspects of sphingosine 1-phosphate biology. Trends Mol. Med. 17, 463–472 (2011).
  Article CAS PubMed Google Scholar
• Orr Gandy, K. A. & Obeid, L. M. Targeting the sphingosine kinase/sphingosine 1-phosphate pathway in disease: review of sphingosine kinase inhibitors. Biochim. Biophys. Acta 1831, 157–166 (2013).
  Article CAS PubMed Google Scholar
• Maceyka, M., Harikumar, K. B., Milstien, S. & Spiegel, S. Sphingosine-1-phosphate signaling and its role in disease. Trends Cell Biol. 22, 50–60 (2012).
  Article CAS PubMed Google Scholar
• Rosen, H., Stevens, R. C., Hanson, M., Roberts, E. & Oldstone, M. B. Sphingosine-1-phosphate and its receptors: structure, signaling, and influence. Annu. Rev. Biochem. 82, 637–662 (2013).
  Article CAS PubMed Google Scholar
• Pyne, N. J. & Pyne, S. Sphingosine 1-phosphate and cancer. Nature Rev. Cancer 10, 489–503 (2010).
  Article CAS Google Scholar
• Spiegel, S. & Milstien, S. The outs and the ins of sphingosine-1-phosphate in immunity. Nature Rev. Immunol. 11, 403–415 (2011).
  Article CAS Google Scholar
• Cyster, J. G. & Schwab, S. R. Sphingosine-1-phosphate and lymphocyte egress from lymphoid organs. Annu. Rev. Immunol. 30, 69–94 (2012).
  Article CAS PubMed Google Scholar
• Cuvillier, O. et al. Suppression of ceramide-mediated programmed cell death by sphingosine-1-phosphate. Nature 381, 800–803 (1996). This paper established the concept of the sphingolipid rheostat complex, in which the balance between ceramide (the pro-apoptotic precursor of S1P) and the anti-apoptotic S1P determines cell fate.
  Article CAS PubMed Google Scholar
• Brinkmann, V. et al. Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis. Nature Rev. Drug Discov. 9, 883–897 (2010).
  Article CAS Google Scholar
• Alvarez, S. E. et al. Sphingosine-1-phosphate is a missing cofactor for the E3 ubiquitin ligase TRAF2. Nature 465, 1084–1088 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Hait, N. C. et al. Regulation of histone acetylation in the nucleus by sphingosine-1-phosphate. Science 325, 1254–1257 (2009). This was the first demonstration that HDACs are direct intracellular targets of S1P and are formed in the nucleus by SPHK2, thus linking nuclear sphingolipid metabolism to gene regulation.
  Article CAS PubMed PubMed Central Google Scholar
• Takasugi, N. et al. BACE1 activity is modulated by cell-associated sphingosine-1-phosphate. J. Neurosci. 31, 6850–6857 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Kim, R. H., Takabe, K., Milstien, S. & Spiegel, S. Export and functions of sphingosine-1-phosphate. Biochim. Biophys. Acta 1791, 692–696 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Kawahara, A. et al. The sphingolipid transporter spns2 functions in migration of zebrafish myocardial precursors. Science 323, 524–527 (2009). This study showed that SPNS2 is an S1P transporter that has an important role in cardiac development in zebrafish. This study led to the later demonstration that mammalian SPNS2 analogues are also S1P transporters.
  Article CAS PubMed Google Scholar
• Nagahashi, M. et al. Spns2, a transporter of phosphorylated sphingoid bases, regulates their blood and lymph levels, and the lymphatic network. FASEB J. 27, 1001–1011 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Hisano, Y., Kobayashi, N., Yamaguchi, A. & Nishi, T. Mouse SPNS2 functions as a sphingosine-1-phosphate transporter in vascular endothelial cells. PLoS ONE 7, e38941 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Fukuhara, S. et al. The sphingosine-1-phosphate transporter Spns2 expressed on endothelial cells regulates lymphocyte trafficking in mice. J. Clin. Invest. 122, 1416–1426 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Mendoza, A. et al. The transporter Spns2 is required for secretion of lymph but not plasma sphingosine-1-phosphate. Cell Rep. 2, 1104–1110 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Breart, B. et al. Lipid phosphate phosphatase 3 enables efficient thymic egress. J. Exp. Med. 208, 1267–1278 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Liang, J. et al. Sphingosine-1-phosphate links persistent STAT3 activation, chronic intestinal inflammation, and development of colitis-associated cancer. Cancer Cell 23, 107–120 (2013).
  Article CAS PubMed Google Scholar
• Mizugishi, K. et al. Essential role for sphingosine kinases in neural and vascular development. Mol. Cell. Biol. 25, 11113–11121 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• Hannun, Y. A. & Obeid, L. M. Principles of bioactive lipid signalling: lessons from sphingolipids. Nature Rev. Mol. Cell. Biol. 9, 139–150 (2008).
  Article CAS Google Scholar
• Lee, H. et al. STAT3-induced S1PR1 expression is crucial for persistent STAT3 activation in tumors. Nature Med. 16, 1421–1428 (2010). This study showed that persistent activation of STAT3 in tumours involves S1P and S1PR1 in a malicious feedforward cycle.
  Article CAS PubMed Google Scholar
• Liu, Y. et al. S1PR1 is an effective target to block STAT3 signaling in activated B cell-like diffuse large B-cell lymphoma. Blood 120, 1458–1465 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Deng, J. et al. S1PR1–STAT3 signaling is crucial for myeloid cell colonization at future metastatic sites. Cancer Cell 21, 642–654 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Nagahashi, M. et al. Sphingosine-1-phosphate produced by sphingosine kinase 1 promotes breast cancer progression by tumor-induced angiogenesis and lymphangiogenesis. Cancer Res. 72, 726–735 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Ponnusamy, S. et al. Communication between host organism and cancer cells is transduced by systemic sphingosine kinase 1/sphingosine 1-phosphate signalling to regulate tumour metastasis. EMBO Mol. Med. 4, 761–775 (2012). This paper highlighted that S1P is involved in the communication between tumours and hosts to regulate metastasis.
  Article CAS PubMed PubMed Central Google Scholar
• Ruckhaberle, E. et al. Microarray analysis of altered sphingolipid metabolism reveals prognostic significance of sphingosine kinase 1 in breast cancer. Breast Cancer Res. Treat. 112, 41–52 (2008).
  Article CAS PubMed Google Scholar
• Kawamori, T. et al. Role for sphingosine kinase 1 in colon carcinogenesis. FASEB J. 23, 405–414 (2008).
  Article CAS PubMed Google Scholar
• Pyne, S., Edwards, J., Ohotski, J. & Pyne, N. J. Sphingosine 1-phosphate receptors and sphingosine kinase 1: novel biomarkers for clinical prognosis in breast, prostate, and hematological cancers. Front. Oncol. 2, 168 (2012).
  Article PubMed PubMed Central Google Scholar
• Paugh, S. W. et al. A selective sphingosine kinase 1 inhibitor integrates multiple molecular therapeutic targets in human leukemia. Blood 112, 1382–1391 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Kharel, Y. et al. Sphingosine kinase type 1 inhibition reveals rapid turnover of circulating sphingosine 1-phosphate. Biochem. J. 440, 345–353 (2011).
  Article CAS PubMed Google Scholar
• Schnute, M. E. et al. Modulation of cellular S1P levels with a novel, potent and specific inhibitor of sphingosine kinase-1. Biochem. J. 444, 79–88 (2012).
  Article CAS PubMed Google Scholar
• Pyne, S., Bittman, R. & Pyne, N. J. Sphingosine kinase inhibitors and cancer: seeking the golden sword of Hercules. Cancer Res. 71, 6576–6582 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Wang, Z. et al. Molecular basis of sphingosine kinase 1 substrate recognition and catalysis. Structure 21, 798–809 (2013).
  Article CAS PubMed Google Scholar
• Chipuk, J. E. et al. Sphingolipid metabolism cooperates with BAK and BAX to promote the mitochondrial pathway of apoptosis. Cell 148, 988–1000 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Gomez, L. et al. A novel role for mitochondrial sphingosine-1-phosphate produced by sphingosine kinase-2 in PTP-mediated cell survival during cardioprotection. Bas. Res. Cardiol. 106, 1341–1353 (2011).
  Article CAS Google Scholar
• Vessey, D. A. et al. A sphingosine kinase form 2 knockout sensitizes mouse myocardium to ischemia/reoxygenation injury and diminishes responsiveness to ischemic preconditioning. Oxid. Med. Cell. Longev. 2011, 961059 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Strub, G. M. et al. Sphingosine-1-phosphate produced by sphingosine kinase 2 in mitochondria interacts with prohibitin 2 to regulate complex IV assembly and respiration. FASEB J. 25, 600–612 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• French, K. J. et al. Pharmacology and antitumor activity of ABC294640, a selective inhibitor of sphingosine kinase-2. J. Pharmacol. Exp. Ther. 333, 129–139 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Antoon, J. W. et al. Antiestrogenic effects of the novel sphingosine kinase-2 inhibitor ABC294640. Endocrinology 151, 5124–5135 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Kharel, Y. et al. Sphingosine kinase type 2 inhibition elevates circulating sphingosine 1-phosphate. Biochem. J. 447, 149–157 (2012).
  Article CAS PubMed Google Scholar
• Samy, E. T. et al. Cutting edge: modulation of intestinal autoimmunity and IL-2 signaling by sphingosine kinase 2 independent of sphingosine 1-phosphate. J. Immunol. 179, 5644–5648 (2007).
  Article CAS PubMed Google Scholar
• Maines, L. W., Fitzpatrick, L. R., Green, C. L., Zhuang, Y. & Smith, C. D. Efficacy of a novel sphingosine kinase inhibitor in experimental Crohn's disease. Inflammopharmacology 18, 73–85 (2010).
  Article CAS PubMed Google Scholar
• Chumanevich, A. A. et al. Suppression of colitis-driven colon cancer in mice by a novel small molecule inhibitor of sphingosine kinase. Carcinogenesis 31, 1787–1793 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Baker, D. A., Barth, J., Chang, R., Obeid, L. M. & Gilkeson, G. S. Genetic sphingosine kinase 1 deficiency significantly decreases synovial inflammation and joint erosions in murine TNF-alpha-induced arthritis. J. Immunol. 185, 2570–2579 (2010).
  Article CAS PubMed Google Scholar
• Fitzpatrick, L. R. et al. Attenuation of arthritis in rodents by a novel orally-available inhibitor of sphingosine kinase. Inflammopharmacology 19, 75–87 (2011).
  Article CAS PubMed Google Scholar
• Kazantsev, A. G. & Thompson, L. M. Therapeutic application of histone deacetylase inhibitors for central nervous system disorders. Nature Rev. Drug Discov. 7, 854–868 (2008).
  Article CAS Google Scholar
• Haberland, M., Montgomery, R. L. & Olson, E. N. The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nature Rev. Genet. 10, 32–42 (2009).
  Article CAS PubMed Google Scholar
• Fischer, A., Sananbenesi, F., Mungenast, A. & Tsai, L. H. Targeting the correct HDAC(s) to treat cognitive disorders. Trends Pharmacol. Sci. 31, 605–617 (2010).
  Article CAS PubMed Google Scholar
• Nakahara, K. et al. The Sjogren–Larsson syndrome gene encodes a hexadecenal dehydrogenase of the sphingosine 1-phosphate degradation pathway. Mol. Cell 46, 461–471 (2012). This study showed that the S1P metabolite hexadecenal is implicated in the pathogenesis of Sjögren–Larsson syndrome as a result of mutations in ALDH3A2 , which is needed to metabolize the hexedecanal produced from S1P by S1P lyase.
  Article CAS PubMed Google Scholar
• Aguilar, A. & Saba, J. D. Truth and consequences of sphingosine-1-phosphate lyase. Adv. Biol. Regul. 52, 17–30 (2012).
  Article CAS PubMed Google Scholar
• Ihlefeld, K., Claas, R. F., Koch, A., Pfeilschifter, J. M. & Meyer Zu Heringdorf, D. Evidence for a link between histone deacetylation and Ca2+ homoeostasis in sphingosine-1-phosphate lyase-deficient fibroblasts. Biochem. J. 447, 457–464 (2012).
  Article CAS PubMed Google Scholar
• Schwab, S. R. et al. Lymphocyte sequestration through S1P lyase inhibition and disruption of S1P gradients. Science 309, 1735–1739 (2005). This important study established that lymphocyte egress is mediated by S1P gradients that are established by S1P lyase activity.
  Article CAS PubMed Google Scholar
• Bagdanoff, J. T. et al. Inhibition of sphingosine 1-phosphate lyase for the treatment of rheumatoid arthritis: discovery of (E)-1-(4-((1_R_,2_S_,3_R_)-1,2,3,4-tetrahydroxybutyl)-1_H_-imidazol-2-yl)ethanone oxime (LX2931) and (1_R_,2_S_,3_R_)-1-(2-(isoxazol-3-yl)-1_H_-imidazol-4-yl)butane-1,2,3,4-tetraol (LX2932). J. Med. Chem. 53, 8650–8662 (2010).
  Article CAS PubMed Google Scholar
• Bourquin, F., Riezman, H., Capitani, G. & Grutter, M. G. Structure and function of sphingosine-1-phosphate lyase, a key enzyme of sphingolipid metabolism. Structure 18, 1054–1065 (2010).
  Article CAS PubMed Google Scholar
• Nagata, Y., Partridge, T. A., Matsuda, R. & Zammit, P. S. Entry of muscle satellite cells into the cell cycle requires sphingolipid signaling. J. Cell Biol. 174, 245–253 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Loh, K. C. et al. Sphingosine-1-phosphate enhances satellite cell activation in dystrophic muscles through a S1PR2/STAT3 signaling pathway. PLoS ONE 7, e37218 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Pantoja, M., Fischer, K. A., Ieronimakis, N., Reyes, M. & Ruohola-Baker, H. Genetic elevation of sphingosine 1-phosphate suppresses dystrophic muscle phenotypes in Drosophila. Development 140, 136–146 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Hanson, M. A. et al. Crystal structure of a lipid G protein-coupled receptor. Science 335, 851–855 (2012). The first X-ray crystal structure of an S1PR, namely S1PR1, was reported in this paper. This structure provided a detailed view of the binding site of S1P and paves the way for the development of more specific agonists and antagonists that could be clinically useful.
  Article CAS PubMed PubMed Central Google Scholar
• Mandala, S. et al. Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science 296, 346–349 (2002). This study elucidated the mechanism of immunosuppression induced by fingolimod and showed that its phosphorylated form signals through S1PR1 to interfere with lymphocyte trafficking.
  Article CAS PubMed Google Scholar
• Brinkmann, V. et al. The immune modulator, FTY720, targets sphingosine 1-phosphate receptors. J. Biol. Chem. 277, 21453–21457 (2002).
  Article CAS PubMed Google Scholar
• Graler, M. H. & Goetzl, E. J. The immunosuppressant FTY720 down-regulates sphingosine 1-phosphate G protein-coupled receptors. FASEB J. 18, 551–553 (2004).
  Article CAS PubMed Google Scholar
• Gonzalez-Cabrera, P. J. et al. S1P1 receptor modulation with cyclical recovery from lymphopenia ameliorates mouse model of multiple sclerosis. Mol. Pharmacol. 81, 166–174 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Neviani, P. et al. FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia. J. Clin. Invest. 117, 2408–2421 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• Gergely, P. et al. The selective S1P receptor modulator BAF312 redirects lymphocyte distribution and has species-specific effects on heart rate: translation from preclinical to clinical studies. Br. J. Pharmacol. 167, 1035–1047 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Komiya, T. et al. Efficacy and immunomodulatory actions of ONO-4641, a novel selective agonist for sphingosine 1-phosphate receptors 1 and 5, in preclinical models of multiple sclerosis. Clin. Exp. Immunol. 171, 54–62 (2013).
  Article CAS PubMed Google Scholar
• Piali, L. et al. The selective sphingosine 1-phosphate receptor 1 agonist ponesimod protects against lymphocyte-mediated tissue inflammation. J. Pharmacol. Exp. Ther. 337, 547–556 (2011).
  Article CAS PubMed Google Scholar
• Willis, M. A. & Cohen, J. A. Fingolimod therapy for multiple sclerosis. Semin. Neurol. 33, 37–44 (2013).
  Article PubMed Google Scholar
• Nolan, R., Gelfand, J. M. & Green, A. J. Fingolimod treatment in multiple sclerosis leads to increased macular volume. Neurology 80, 139–144 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Quancard, J. et al. A potent and selective S1P1 antagonist with efficacy in experimental autoimmune encephalomyelitis. Chem. Biol. 19, 1142–1151 (2012).
  Article CAS PubMed Google Scholar
• Choi, J. W. et al. FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation. Proc. Natl Acad. Sci. USA 108, 751–756 (2011).
  Article PubMed Google Scholar
• Sanna, M. G. et al. Enhancement of capillary leakage and restoration of lymphocyte egress by a chiral S1P1 antagonist in vivo. Nature Chem. Biol. 2, 434–441 (2006).
  Article CAS Google Scholar
• Teijaro, J. R. et al. Endothelial cells are central orchestrators of cytokine amplification during influenza virus infection. Cell 146, 980–991 (2011). This study showed that S1PR1 agonists can suppress cytokines and innate immune cell recruitment, and it identified endothelial cells as central regulators of the cytokine storm induced by viral infections.
  Article CAS PubMed PubMed Central Google Scholar
• Matsuoka, Y., Nagahara, Y., Ikekita, M. & Shinomiya, T. A novel immunosuppressive agent FTY720 induced Akt dephosphorylation in leukemia cells. Br. J. Pharmacol. 138, 1303–1312 (2003).
  Article CAS PubMed PubMed Central Google Scholar
• Liu, Q. et al. FTY720 demonstrates promising preclinical activity for chronic lymphocytic leukemia and lymphoblastic leukemia/lymphoma. Blood 111, 275–284 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Roberts, K. G. et al. Essential requirement for PP2A inhibition by the oncogenic receptor c-KIT suggests PP2A reactivation as a strategy to treat c-KIT+ cancers. Cancer Res. 70, 5438–5447 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Wang, Z., Jiang, H., Chen, S., Du, F. & Wang, X. The mitochondrial phosphatase PGAM5 functions at the convergence point of multiple necrotic death pathways. Cell 148, 228–243 (2012).
  Article CAS PubMed Google Scholar
• Sun, L. et al. Mixed lineage kinase domain-like protein mediates necrosis signaling downstream of RIP3 kinase. Cell 148, 213–227 (2012).
  Article CAS PubMed Google Scholar
• Yu, H., Kortylewski, M. & Pardoll, D. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nature Rev. Immunol. 7, 41–51 (2007).
  Article CAS Google Scholar
• Ding, B. B. et al. Constitutively activated STAT3 promotes cell proliferation and survival in the activated B-cell subtype of diffuse large B-cell lymphomas. Blood 111, 1515–1523 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Yu, H., Pardoll, D. & Jove, R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nature Rev. Cancer 9, 798–809 (2009).
  Article CAS Google Scholar
• Liu, Y. et al. Edg-1, the G protein-coupled receptor for sphingosine-1-phosphate, is essential for vascular maturation. J. Clin. Invest. 106, 951–961 (2000). This is the first demonstration of the essential role of S1PR1 in vascular integrity.
  Article CAS PubMed PubMed Central Google Scholar
• Shoham, A. B. et al. S1P1 inhibits sprouting angiogenesis during vascular development. Development 139, 3859–3869 (2012).
  Article CAS PubMed Google Scholar
• Gaengel, K. et al. The sphingosine-1-phosphate receptor S1PR1 restricts sprouting angiogenesis by regulating the interplay between VE-cadherin and VEGFR2. Dev. Cell 23, 587–599 (2012).
  Article CAS PubMed Google Scholar
• Jung, B. et al. Flow-regulated endothelial S1P receptor-1 signaling sustains vascular development. Dev. Cell 23, 600–610 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Ishii, M. et al. Sphingosine-1-phosphate mobilizes osteoclast precursors and regulates bone homeostasis. Nature 458, 524–528 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Ishii, M., Kikuta, J., Shimazu, Y., Meier-Schellersheim, M. & Germain, R. N. Chemorepulsion by blood S1P regulates osteoclast precursor mobilization and bone remodeling in vivo. J. Exp. Med. 207, 2793–2798 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Kikuta, J. et al. Sphingosine-1-phosphate-mediated osteoclast precursor monocyte migration is a critical point of control in antibone-resorptive action of active vitamin D. Proc. Natl Acad. Sci. USA 110, 7009–7013 (2013).
  Article PubMed PubMed Central Google Scholar
• Long, J. S. et al. Sphingosine 1-phosphate receptor 4 uses HER2 (ERBB2) to regulate extracellular signal regulated kinase-1/2 in MDA-MB-453 breast cancer cells. J. Biol. Chem. 285, 35957–35966 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Salomone, S. & Waeber, C. Selectivity and specificity of sphingosine-1-phosphate receptor ligands: caveats and critical thinking in characterizing receptor-mediated effects. Front. Pharmacol. 2, 9 (2011).
  PubMed PubMed Central Google Scholar
• Sukocheva, O. et al. Estrogen transactivates EGFR via the sphingosine 1-phosphate receptor Edg-3: the role of sphingosine kinase-1. J. Cell Biol. 173, 301–310 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Watson, C. et al. High expression of sphingosine 1-phosphate receptors, S1P1 and S1P3, sphingosine kinase 1, and extracellular signal-regulated kinase-1/2 is associated with development of tamoxifen resistance in estrogen receptor-positive breast cancer patients. Am. J. Pathol. 177, 2205–2215 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Harris, G. L., Creason, M. B., Brulte, G. B. & Herr, D. R. In vitro and in vivo antagonism of a G protein-coupled receptor (S1P3) with a novel blocking monoclonal antibody. PLoS ONE 7, e35129 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Sammani, S. et al. Differential effects of sphingosine 1-phosphate receptors on airway and vascular barrier function in the murine lung. Am. J. Respir. Cell. Mol. Biol. 43, 394–402 (2010).
  Article CAS PubMed Google Scholar
• Niessen, F. et al. Dendritic cell PAR1–S1P3 signalling couples coagulation and inflammation. Nature 452, 654–658 (2008).
  Article CAS PubMed Google Scholar
• Sun, X. et al. Sphingosine-1-phosphate receptor-3 is a novel biomarker in acute lung injury. Am. J. Respir. Cell. Mol. Biol. 47, 628–636 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Schulze, T. et al. Sphingosine-1-phospate receptor 4 (S1P4) deficiency profoundly affects dendritic cell function and TH17-cell differentiation in a murine model. FASEB J. 25, 4024–4036 (2011).
  Article CAS PubMed Google Scholar
• Allende, M. L. et al. Sphingosine-1-phosphate lyase deficiency produces a pro-inflammatory response while impairing neutrophil trafficking. J. Biol. Chem. 286, 7348–7358 (2011).
  Article CAS PubMed Google Scholar
• Urbano, M. et al. SAR analysis of innovative selective small molecule antagonists of sphingosine-1-phosphate 4 (S1P4) receptor. Bioorg. Med. Chem. Lett. 21, 5470–5474 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Jenne, C. N. et al. T-bet-dependent S1P5 expression in NK cells promotes egress from lymph nodes and bone marrow. J. Exp. Med. 206, 2469–2481 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Mattes, H. et al. Design and synthesis of selective and potent orally active S1P5 agonists. ChemMedChem 5, 1693–1696 (2010).
  Article PubMed Google Scholar
• Yang, L. et al. Sphingosine kinase/sphingosine 1-phosphate (S1P)/S1P receptor axis is involved in liver fibrosis-associated angiogenesis. J. Hepatol. 59, 114–123 (2013).
  Article CAS PubMed Google Scholar
• Kapitonov, D. et al. Targeting sphingosine kinase 1 inhibits Akt signaling, induces apoptosis, and suppresses growth of human glioblastoma cells and xenografts. Cancer Res. 69, 6915–6923 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Price, M. M. et al. A specific sphingosine kinase 1 inhibitor attenuates airway hyperresponsiveness and inflammation in a mast cell-dependent mouse model of allergic asthma. J. Allergy Clin. Immunol. 131, 501–511 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Dickson, M. A. et al. A phase I clinical trial of safingol in combination with cisplatin in advanced solid tumors. Clin. Cancer Res. 17, 2484–2492 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Gao, P., Peterson, Y. K., Smith, R. A. & Smith, C. D. Characterization of isoenzyme-selective inhibitors of human sphingosine kinases. PLoS ONE 7, e44543 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Antoon, J. W. et al. Pharmacological inhibition of sphingosine kinase isoforms alters estrogen receptor signaling in human breast cancer. J. Mol. Endocrinol. 46, 205–216 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Liu, Q. et al. Inhibition of sphingosine kinase-2 suppresses inflammation and attenuates graft injury after liver transplantation in rats. PLoS ONE 7, e41834 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Finney, C. A. et al. S1P is associated with protection in human and experimental cerebral malaria. Mol. Med. 17, 717–725 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Scuto, A. et al. STAT3 inhibition is a therapeutic strategy for ABC-like diffuse large B-cell lymphoma. Cancer Res. 71, 3182–3188 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Saddoughi, S. A. et al. Sphingosine analogue drug FTY720 targets I2PP2A/SET and mediates lung tumour suppression via activation of PP2A-RIPK1-dependent necroptosis. EMBO Mol. Med. 5, 105–121 (2013).
  Article CAS PubMed Google Scholar
• Shimizu, H. et al. KRP-203, a novel synthetic immunosuppressant, prolongs graft survival and attenuates chronic rejection in rat skin and heart allografts. Circulation 111, 222–229 (2005).
  Article CAS PubMed Google Scholar
• Suzuki, C. et al. Efficacy of mycophenolic acid combined with KRP-203, a novel immunomodulator, in a rat heart transplantation model. J. Heart Lung Transplant. 25, 302–309 (2006).
  Article PubMed Google Scholar
• Song, J. et al. A novel sphingosine 1-phosphate receptor agonist, 2-amino-2-propanediol hydrochloride (KRP-203), regulates chronic colitis in interleukin-10 gene-deficient mice. J. Pharmacol. Exp. Ther. 324, 276–283 (2008).
  Article CAS PubMed Google Scholar
• Wenderfer, S. E., Stepkowski, S. M. & Braun, M. C. Increased survival and reduced renal injury in MRL/lpr mice treated with a novel sphingosine-1-phosphate receptor agonist. Kidney Int. 74, 1319–1326 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Poti, F. et al. Effect of sphingosine 1-phosphate (S1P) receptor agonists FTY720 and CYM5442 on atherosclerosis development in LDL receptor deficient (LDL-R−/−) mice. Vascul. Pharmacol. 57, 56–64 (2012).
  Article CAS PubMed Google Scholar
• Zhang, Z. Y. et al. AUY954, a selective S1P1 modulator, prevents experimental autoimmune neuritis. J. Neuroimmunol. 216, 59–65 (2009).
  Article CAS PubMed Google Scholar
• Galicia-Rosas, G. et al. A sphingosine-1-phosphate receptor 1-directed agonist reduces central nervous system inflammation in a plasmacytoid dendritic cell-dependent manner. J. Immunol. 189, 3700–3706 (2012).
  Article CAS PubMed Google Scholar
• Lien, Y. H., Yong, K. C., Cho, C., Igarashi, S. & Lai, L. W. S1P1-selective agonist, SEW2871, ameliorates ischemic acute renal failure. Kidney Int. 69, 1601–1608 (2006).
  Article CAS PubMed Google Scholar
• Awad, A. S. et al. Chronic sphingosine 1-phosphate 1 receptor activation attenuates early-stage diabetic nephropathy independent of lymphocytes. Kidney Int. 79, 1090–1098 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Jo, E. et al. S1P1-selective _in vivo_-active agonists from high- throughput screening: off-the-shelf chemical probes of receptor interactions, signaling, and fate. Chem. Biol. 12, 703–715 (2005).
  Article CAS PubMed Google Scholar
• Nishi, T. et al. Discovery of CS-0777: a potent, selective, and orally active S1P1 agonist. ACS Med. Chem. Lett. 2, 368–372 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Marsolais, D. et al. A critical role for the sphingosine analog AAL-R in dampening the cytokine response during influenza virus infection. Proc. Natl Acad. Sci. USA 106, 1560–1565 (2009).
  Article PubMed PubMed Central Google Scholar
• Fujii, Y. et al. Amelioration of collagen-induced arthritis by a novel S1P1 antagonist with immunomodulatory activities. J. Immunol. 188, 206–215 (2012).
  Article CAS PubMed Google Scholar
• Gonzalez-Cabrera, P. J. et al. Full pharmacological efficacy of a novel S1P1 agonist that does not require S1P-Like headgroup interactions. Mol. Pharmacol. 74, 1308–1318 (2008).
  Article CAS PubMed Google Scholar
• Davis, M. D., Clemens, J. J., Macdonald, T. L. & Lynch, K. R. Sphingosine 1-phosphate analogs as receptor antagonists. J. Biol. Chem. 280, 9633–9641 (2005).
  Article CAS Google Scholar
• Tarrason, G. et al. The sphingosine-1-phosphate receptor-1 antagonist, W146, causes early and short-lasting peripheral blood lymphopenia in mice. Int. Immunopharmacol. 11, 1773–1779 (2011).
  Article CAS PubMed Google Scholar
• Finley, A. et al. Sphingosine 1-phosphate mediates hyperalgesia via a neutrophil-dependent mechanism. PLoS ONE 8, e55255 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Kluk, M. J. et al. Sphingosine-1-phosphate receptor 1 in classical Hodgkin lymphoma: assessment of expression and role in cell migration. Lab. Invest. 93, 462–471 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Foss, F. W. Jr et al. Synthesis and biological evaluation of γ-aminophosphonates as potent, subtype-selective sphingosine 1-phosphate receptor agonists and antagonists. Bioorg. Med. Chem. 15, 663–677 (2007).
  Article CAS PubMed Google Scholar
• Skoura, A. et al. Sphingosine-1-phosphate receptor-2 function in myeloid cells regulates vascular inflammation and atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 31, 81–85 (2011).
  Article CAS PubMed Google Scholar
• Ikeda, H. et al. Antiproliferative property of sphingosine 1-phosphate in rat hepatocytes involves activation of Rho via Edg-5. Gastroenterology 124, 459–469 (2003).
  Article CAS PubMed Google Scholar
• Bolli, M. H. et al. 2-imino-thiazolidin-4-one derivatives as potent, orally active S1P1 receptor agonists. J. Med. Chem. 53, 4198–4211 (2010).
  Article CAS PubMed Google Scholar
• Visentin, B. et al. Validation of an anti-sphingosine-1-phosphate antibody as a potential therapeutic in reducing growth, invasion, and angiogenesis in multiple tumor lineages. Cancer Cell 9, 225–238 (2006).
  Article CAS PubMed Google Scholar
• Caballero, S. et al. Anti-sphingosine-1-phosphate monoclonal antibodies inhibit angiogenesis and sub-retinal fibrosis in a murine model of laser-induced choroidal neovascularization. Exp. Eye Res. (2008).
• Sanada, Y. et al. Therapeutic effects of novel sphingosine-1-phosphate receptor agonist W-061 in murine DSS colitis. PLoS ONE 6, e23933 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Clemens, J. J., Davis, M. D., Lynch, K. R. & Macdonald, T. L. Synthesis of benzimidazole based analogues of sphingosine-1-phosphate: discovery of potent, subtype-selective S1P4 receptor agonists. Bioorg. Med. Chem. Lett. 14, 4903–4906 (2004).
  Article CAS PubMed Google Scholar
• Ota, H. et al. S1P4 receptor mediates S1P-induced vasoconstriction in normotensive and hypertensive rat lungs. Pulm. Circ. 1, 399–404 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Song, J., Hagiya, H., Kurata, H., Mizuno, H. & Ito, T. Prevention of GVHD and graft rejection by a new S1P receptor agonist, W-061, in rat small bowel transplantation. Transpl. Immunol. 26, 163–170 (2012).
  Article CAS PubMed Google Scholar